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OBJECTIVES We sought to evaluate the surgical results and effects of continuous support with the
permanent Jarvik-2000 left ventricular assist device (LVAD). We report the early outcomes.
BACKGROUND A shortage of transplant donors necessitates the testing of alternative treatments. The
Jarvik-2000 is an axial flow pump with a percutaneous retro-auricular power connector,
designed for permanent use.
METHODS Patients with severe heart failure (HF), unsuitable for heart transplantation or conventional
LVAD support, were offered implantation. The surgical approach included a left lateral
thoracotomy. The device was implanted into the left ventricular apex on femoro-femoral
bypass. It is set to allow pulsatile flow with an aortic valve opening. Anticoagulation is
adjusted the same as for patients with a heart valve.
RESULTS Between May 2001 and August 2001, we implanted the Jarvik-2000 in two patients with
dilated cardiomyopathy and in one with cardiac amyloidosis, all with severe HF (cardiac index
1.8 0.3 l/m2 per min). One patient required preoperative inotropic support. All patients did
well, with no repeat operations or infections. Patients received 4.3  3.2 packed red blood
cells and were intubated at 14  3 h, and the intensive care unit stay was 7.0  0.5 days. The
cardiac index increased from 3.7  1.5 l/min per m2 at 8,000 rpm to 5.9  2.9 l/min per m2
at 12,000 rpm. All patients currently have mild hemolysis not requiring transfusion. The
following postoperative events were recorded: a transient ischemic attack with complete
recovery, a short re-intubation due to ventricular arrhythmia, loss of consciousness with a
battery change while standing, knee-joint effusion after ergometry training, a minor wound
problem and a short hospital re-admission due to dehydration. Patients were discharged
home after 49  7 days; one has returned to work. All quality-of-life scores have improved.
CONCLUSIONS The permanent Jarvik-2000 appears safe. It can be used for dilative or restrictive disease. The
Jarvik-2000 might prove a valid option for the long-term treatment of patients with severe
HF. (J Am Coll Cardiol 2002;39:1764–72) © 2002 by the American College of Cardiology
Foundation
We tested the Jarvik-2000 permanent left ventricular assist
device (LVAD) as a potential alternative to heart transplan-
tation. The Jarvik-2000 is a novel axial flow LVAD (1,2)
designed for permanent use (Fig. 1A). Conventional
LVADs have been shown to improve survival in terminal
heart failure (HF) patients awaiting transplantation (3).
However, LVADs are associated with significant complica-
tions (4). Over 50% of patients treated with conventional
left ventricular (LV) support will have a life-threatening
event (5–9). Conventional assist devices are impractical for
daily life. Taking all these problems into consideration,
LVADs are not an equivalent alternative to heart transplan-
tation.
The Jarvik-2000 is small and has several advantages in its
design, so as to reduce complications associated with con-
ventional mechanical circulatory support. It is designed for
long-term use. The power cable is connected to a percuta-
neous retro-auricular skull-mounted pedestal (Fig. 1B). The
portable batteries and control unit weigh 1.5 kg, allowing
patients to lead an independent life-style. We report our
early experience with this device.
METHODS
The study protocol and patient information brochure have
been reviewed and approved by the local Ethics Committee.
The patient selection and preoperative work-up were in
accordance with predetermined guidelines.
Patient selection. Patients with end-stage HF, who had
no conventional treatment option, were considered for
Jarvik-2000 implantation. Table 1 lists the inclusion and
exclusion criteria for implantation of the Jarvik-2000
LVAD. Heart failure criteria for transplantation or me-
chanical LV support had to be present. Patients who did not
qualify for heart transplantation, because of advanced age or
elevated pulmonary vascular resistance, or patients unsuit-
able for a conventional LVAD because of a small body
frame, with a body surface area 1.5 m2, were eligible for
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Jarvik-2000 implantation. We did not offer the Jarvik-2000
to patients with fixed pulmonary vascular resistance 7
wood units (WU), because of the high risk of postoperative
right ventricular (RV) failure. Only patients with a Colum-
bia University risk score index 5 were considered for
implantation (10). This score, used for patient risk stratifi-
cation, is based on the following clinical variables: central
venous pressure, urine output, respiratory status, hepatic
synthetic function, previous cardiac surgery and leukocyte
count. Most patients with a score 5 will die after LVAD
implantation (10).
Preoperative evaluation. The patient was evaluated the
same as for heart transplantation (11). This involves right
and left heart catheterization, transesophageal echocardiog-
raphy (TEE), carotid duplex scanning, abdominal ultra-
sonography, pulmonary function testing, exercise ergonom-
etry and a full laboratory work-up. In addition, a computed
tomographic (CT) scan of the head and chest was obtained.
The CT scan allows site selection for the outflow graft
anastomosis and placement of the skull-mounted pedestal in
an area with thick bone (4 mm). A full evaluation by a
neurologist was performed. Preoperative quality of life was
assessed by use of a standardized questionnaire (12,13).
Patient and family information includes detailed discus-
sions and a brochure in layman language explaining the
potential risks, benefits and alternatives of the planned
procedure. Sufficient time is allowed for questions and the
decision-making process before full informed consent is
obtained.
Intraoperative management. Intraoperative monitoring
included TEE and a Swan-Ganz catheter. Aprotinin and
nitric oxide (5 to 80 ppm) were used routinely. The
retro-auricular pedestal site was prepared. A left postero-
lateral thoracotomy incision was performed. The internal
power cable of the device was passed through the posterior
apex of the chest and tunneled to the pedestal, which was
attached to the skull (Fig. 1B, inset). Then the outflow graft
was sewn to the descending thoracic aorta in partial occlu-
sion. Conventional femoro-femoral bypass was instituted. A
sewing ring was attached to the left ventricular apex. The
heart was fibrillated. The device was implanted into the LV
apex and secured to the sewing ring. Complete de-airing
was confirmed with TEE before unclamping the outflow
graft. Cardiopulmonary bypass was discontinued, and me-
ticulous hemostasis was secured before thoracotomy closure.
Postoperative management. The pump was set to the
minimal speed, keeping the LV in a partially loaded state,
with aortic valve opening. Infection prophylaxis included
48 h of perioperative antibiotics, antibiotic-coated catheters,
catheter removal within two days, early extubation followed
by incentive spirometry and aggressive mobilization. In the
absence of bleeding, intravenous heparin (500 IU/h) was
Abbreviations and Acronyms
CT  computed tomography
HF  heart failure
INR  international normalized ratio
LV  left ventricle/ventricular
LVAD  left ventricular assist device
RV  right ventricular
TEE  transesophageal echocardiography
WU  wood units
Figure 1. (A) The Jarvik-2000 left ventricular assist device is shown before
implantation. Note that the device is only slightly larger than the surgeon’s
thumb. (B) The power cable connected to the percutaneous skull-mounted
pedestal is shown. There were no problems at the skin exit site. The black
power plug connected to the percutaneous pedestal is waterproof, and the
patient is able to take a shower. The inset shows an intraoperative view of
the percutaneous skull-mounted pedestal.
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started 12 h after the operation. On the second postopera-
tive day, heparin was adjusted to full anticoagulation, with
an activated partial thromboplastin time of 50 to 70 s.
Coumadin (warfarin), as well as the pharmacologic HF
treatment, including angiotensin-converting enzyme inhib-
itors and beta-blockers, was started as soon as the patient
could tolerate oral intake. Diuretics could be gradually
reduced. Patients visited a formal two-day teaching course
Table 1. Inclusion and Exclusion Criteria for Permanent Jarvik-2000 Implantation
Inclusion criteria
General Not a candidate for heart transplantation and in need of an assist device;
candidate for transplantation, but no heart immediately available and patient
anatomy precludes a conventional assist device
Cardiac function
(2 of 3 criteria)
LVEF 30%; V˙O2max 16 ml O2/kg per min; cardiac index 2.3 l/m
2 per min
Anatomy BSA between 1.2 and 2.2 m2
Exclusion criteria (absolute criteria/relative criteria)
Neurology, psychology Intracranial bleeding within 21 days; S/p CPR for 5 min and neurologic
outcome unknown; severe brain damage, with no hope for a meaningful
recovery; high probability of noncompliance
Pulmonary Fixed pulmonary vascular resistance 7 WU; pulmonary vascular resistance 5–7
WU, FIO2 0.6
Surgical/medical Malignancy, life expectancy 18 months; untreated aortic dissection or
aneurysms; implanted mechanical heart valve; aortic or mitral insufficiency grade 3
or 4
Renal Anuria, creatinine clearance 25 ml/h; creatinine 3.0, urine output 30 ml/h 
12 h
Liver Cirrhosis (Child C); synthetic dysfunction (INR 1.8, PT 16)
Infection Sepsis or other severe infection
Hematology Contraindication to heparin anticoagulation; thrombus in any cardiac chamber;
history of thromboembolic events
Gastrointestinal tract Ischemic bowel necrosis; GI bleeding (6 U PRBCs) due to diffuse gastritis or
colitis
Time to hospital Transport to hospital 180 min
Risk-score index (10) Columbia risk-score index 5
BSA  body surface area; FIO2  concentration of inspired oxygen; GI  gastrointestinal; INR  international normalized
ratio; LVEF  left ventricular ejection fraction; PRBCs  packed red blood cells; PT  prothrombin time; s/p CPR  status
post cardiopulmonary resuscitation; V˙O2max  maximal oxygen consumption; WU  wood units.
Table 2. Preoperative Patient Characteristics
Patient 1 Patient 2 Patient 3 Mean  SD
Age (yrs) 59.5 62.3 64.9 62.2  2.3
Gender (M/F) M M M
Size (cm) 186 162 179 176  12
Weight (kg) 77 52 76 68  14
Peripheral edema 3  2–3
Body surface area (m2) 1.95 1.53 1.88 1.79  0.23
Disease process DCM DCM A
Length of disease (yrs) 9 10 4 *
Cardiac index (l/m2 per min) 1.8 2.1 1.6 1.8  0.3
Left ventricular ejection fraction (%) 10 15 40 *
V˙O2max (ml O2/kg per min) 13.9† 11.8 7.5 *
Mitral insufficiency (grades 1–4) 3–4 3 2 *
End-diastolic diameter (mm) 90 64 48 *
Preoperative inotropes   
Hepatic synthetic dysfunction, PT 16   
Intubated/urine output 30 ml/h / / /
Leukocytes (103/l) 12.2 9.4 4.7 8.8  3.8
Central venous pressure 16 cm H2O   
Risk-score index (10) 2 0 2 1.3  1.2
Quality-of-life score (12) 65.0 87.5 73.0 75.2  11.4
No HTx or conventional LVAD due to: PVR BSA A
*No mean SD value calculated because of incomparable data or a different disease process. †Measured two months preoperatively;
the actual V˙O2max could not be measured because of the patient’s marginal condition.
A amyloidosis of the heart; DCM dilated cardiomyopathy; HTx heart transplantation; LVAD left ventricular assist
device; PVR  pulmonary vascular resistance; other abbreviations as in Table 1.
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for Coumadin management and received a device to check
their international normalized ratio (INR) at home. Reha-
bilitation was started in the hospital and consisted of bicycle
ergometry, walking and strengthening exercises with phys-
ical therapy. Systematic teaching of the functions and
handling of the device components, as well as emergency
algorithms, was provided to the patients and their relatives.
After hospital discharge, a multidisciplinary team provided
outpatient follow-up.
RESULTS
Between May 2001 and August 2001, we implanted the
Jarvik-2000 in three patients. Table 2 lists the patients’
Table 3. Intraoperative and Postoperative Patient Data
Patient 1 Patient 2 Patient 3 Mean  SD
Operative time (min) 285 275 295 285  10
Cardiopulmonary bypass time (min) 70 68 48 62  12
Ventricular fibrillation time (min) 12 16 8 12  4
Intraoperative transfusion (PRBCs) 0 0 2 0.7  1.2
Postoperative transfusion (PRBCs) 2 3 6 3.7  2.1
Intubation time (h) 12 18 13 14  3
Vasomotor support* (days) 5.5 2.6 4.6 4.2  1.5
ICU length of stay (days) 7.6 6.6 6.6 7.0  0.5
Re-intubation (h) 7  
Postoperative ventricular arrhythmia   
Re-operation   
Infection   
Wound problem   minor
Transient ischemic attack   
LOC with battery change   
Postoperative psychological therapy   
Hospital discharge to home yes yes yes
Hospital length of stay (days) 42 49 55 49  7
Hospital re-admission (days) 1  
Quality-of-life score after 2 months (12) 41.0 8.5 40.5 30.0  18.6
Resumed work   
Supported by device (days) 170 93 91
*Intravenous alpha-agonists and Pitressin were used to treat postoperative vasodilation.
ICU  intensive care unit; LOC  loss of consciousness; PRBCs  packed red blood cells.
Figure 2. The cardiac index of three patients as a function of the rotational speed of the Jarvik-2000 left ventricular assist device, measured with a
Swan-Ganz catheter, one day after implantation.
1767JACC Vol. 39, No. 11, 2002 Siegenthaler et al.
June 5, 2002:1764–72 Jarvik-2000 LVAD Implantation
Figure 3. Mild hemolysis after Jarvik-2000 implantation. The hemoglobin levels (A) became stabilized after the postoperative period. The persistent
elevation of lactate dehydrogenase (LDH) levels (B) and reticulocytes (C) associated with decreased haptoglobin-levels (D) indicate some degree of trauma
to the red blood cells. Note that Patient 3 was transfused on day 17; all other transfusions were given in the early postoperative period.
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pre-implantation characteristics. Two patients had dilated
cardiomyopathy and one patient had amyloidosis. One
patient required preoperative inotropic support with
14 g/kg body weight per min of dobutamine. Follow-up
included over 350 patient-days (91, 93 and 170 days). All
patients are doing well. There were no device failures.
Intraoperative results. Table 3 shows the intraoperative
data. No problems related to the cardiovascular procedure
were encountered. Operating times were 4 to 5 h; cardio-
pulmonary bypass times decreased slightly as we gained
experience. The patient with amyloidosis had friable tissues,
which led to several pleural tears with lung lacerations;
Figure 3. (Continued).
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treatment included fibrin glue and TachoComb (Nycomed,
Munich, Germany). There were no further sequelae. Only
one patient with a preoperative hemoglobin level of 9.8
gm/dl required intraoperative transfusion (2 U packed red
blood cells and 4 U fresh-frozen plasma).
Postoperative results. Table 3 lists the postoperative data.
All patients were extubated on the first postoperative day
(14 3 h). Postoperative blood requirements were low with
the Jarvik-2000 LVAD, compared with traditional LVAD
implantation. Swan-Ganz catheters were removed early
(2.3  0.5 days). Figure 2 shows the cardiac index on the
first postoperative day, as a function of the pump setting.
The intensive care unit stay was seven days, due to a
prolonged need for vasomotor support with alpha-agonists
and vasopressin (Pitressin; 4.2  1.5 days) to maintain a
mean arterial pressure of 65 mm Hg. All patients presently
have mild hemolysis not requiring transfusion, stable hemo-
globin levels, increased lactate dehydrogenase levels, slightly
increased reticulocytes and low haptoglobin levels, as illus-
trated in Figure 3. The end-diastolic diameters of the two
patients with dilated cardiomyopathy decreased with post-
operative unloading. There were two major postoperative
events. One patient had a transient ischemic attack mani-
fested by right arm weakness, which completely resolved
within 30 min. The CT scan and examination, performed
by a neurologist, were normal. No intracardiac thrombus
was found on the echocardiogram. The other event included
one 7-h re-intubation in the early postoperative period, due
to ventricular arrhythmia. The patient, with known Lown
IVa arrhythmia, had an episode of sustained ventricular
tachycardia, during which he remained awake. He was
sedated and intubated for electrical defibrillation. Several
minor events were recorded, including an episode of loss of
consciousness with a battery change while standing, a
significant knee effusion after vigorous ergometry training, a
large skin abrasion from adhesive tape in the patient with
amyloidosis and a one-day hospital re-admission due to
dehydration during the summer heat. All patients were fully
ambulatory within 10 days and were able to climb stairs
within two to three weeks. Two patients required postop-
erative psychological therapy. All patients were discharged
home after a postoperative hospital stay of 49  7 days, and
they live independently. One patient has returned to work.
All patients’ quality-of-life scores improved two months
after implantation.
DISCUSSION
Current treatment options. Heart transplantation, against
which alternative methods should be measured, remains the
standard therapy for patients with end-stage HF. Because of
a shortage of donors, multiple alternative methods of
treatment have been investigated (14–16), including me-
chanical assist systems that were introduced in the 1960s. In
theory, mechanical assist systems could offer advantages
over heart transplantation, including the avoidance of com-
plications related to immunosuppression and its availability
to more patients in need. The initial enthusiasm for assist
systems was followed by a long period of discouragement,
due to high mortality and frequent complications. The main
problems associated with LVADs include selection of ap-
propriate patients, bleeding, RV failure, infection and
thromboembolic complications (4). Over 50% of patients
receiving a conventional LVAD will have one or more
potentially life-threatening complications (5–9). Despite
these problems, conventional LVADs have improved sur-
vival in terminal HF patients awaiting transplantation (3).
The Jarvik-2000 LVAD offers new concepts in its design,
potentially reducing device-associated complications. If the
results continue to be as encouraging as those in our early
experience, this device may become a true option for the
long-term treatment of terminal heart disease.
Patient selection. Choosing the right patients for LVAD
support poses a difficult problem. Oz et al. (10), at Colum-
bia University, have established a score for risk stratification
of patients, which we have used for bedside decision-
making. Implantation of the LVAD in patients with multi-
system organ failure will result in a prohibitively high
mortality rate, regardless of the device chosen (10). In the
early phase of device testing, we preferred to offer this
therapy to patients with a risk score index 5 in order to
avoid offering this expensive therapy to patients who are
unlikely to benefit and to recognize the potential morbidity
inflicted by the device. It is important to emphasize that the
patients in our series were in better preoperative condition
than many patients requiring mechanical support. Yet, all of
the patients were in dire need of LV support and had
contraindications to heart transplantation or conventional
ventricular support, as illustrated in Table 2.
Bleeding and RV failure. Conventional LVAD implanta-
tion is associated with a high rate of bleeding (4,8), often
requiring a repeat operation, thus increasing the risk of
postoperative RV failure (17). In our patients, we noted no
bleeding complications, no RV failure and a low transfusion
requirement after Jarvik-2000 implantation. Several factors
might have been responsible for this: the surgeons’ aware-
ness of the high morbidity associated with bleeding, the
routine use of aprotinin, a smaller surgical procedure,
compared with conventional LVAD implantation, using a
lateral thoracotomy, short cardiopulmonary bypass times
and the absence of severe preoperative coagulopathy. Apro-
tinin reduces the transfusion requirements and mortality
after LVAD implantation and also potentially reduces the
incidence of RV failure (17). In addition, unloading of the
right ventricle with routine use of nitric oxide (5 to 80 ppm)
decreases the pulmonary artery pressure and improves
LVAD flow, although no beneficial effect on mortality has
been shown (18,19).
Infection. Infections occur in 30% to 50% of patients in a
series of conventional LVAD implantations (5,7,20). Drive-
line and peri-implant infections, as well as LVAD endocar-
ditis, cannot generally be cleared without removing the
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device at the time of transplantation. The majority of
infections associated with LVAD do not appear to have a
negative effect on the outcomes of heart transplantation (5).
We have encountered no infectious complications after
Jarvik-2000 implantation. Factors that may potentially re-
duce the risk of infection include a strict infection control
policy and a small amount of surgically implanted foreign
material. The different power supply by means of an
immobile skin exit site in the left retro-auricular area
probably has been the most important factor (Fig. 1B).
Clinical experience with early cochlear implants, using
similar percutaneous skull-mounted pedestals for power
supply, demonstrated a low rate of complications, including
infection (21). Other advantages of this mode of power
supply include only minimal interference with daily activi-
ties and the waterproof power plug, which allows the
patients to shower. This skull-mounted power connector
will soon be released for clinical testing in the United States.
Thromboembolism. Thromboembolic events are often
devastating complications after successful LVAD implanta-
tion. To potentially reduce thromboembolic events, the
Jarvik-2000 is implanted directly into the LV with no inflow
cannula, and the outflow graft is anastomosed into the
descending thoracic aorta. The device is set at a minimal
pump speed to allow aortic valve opening, thus preventing
potential thrombus formation in areas of stasis in the LV
outflow tract and aortic root. All of these factors can
potentially reduce the incidence of thromboembolism. One
of our patients had a transient ischemic attack, likely due to
a small embolus. At the time, his INR was subtherapeutic at
1.8. Based on this single event, we did not change the
anticoagulation regimen, adjusting Coumadin to an INR of
2.0 to 2.5. To date, we intend to avoid giving platelet
inhibitors together with Coumadin because of the increased
risk of bleeding complications in other patient cohorts (22).
Chronic nonpulsatile flow. The effects of chronic nonpul-
satile flow are unknown; therefore, we avoided exposing our
patients to it. The Jarvik-2000 is set to allow aortic valve
opening with a palpable pulse. The concept of this device is
new, as it is truly assisting and not replacing LV function,
keeping the ventricle in a slightly loaded state. It should
therefore not be used in patients with virtually absent
contractile function. Conventional LVADs are more suit-
able to support such patients. To be more accurate, they
should probably be called “LV replacement systems,” as they
completely replace native heart function, with the aortic
valve permanently closed. Interestingly, the Jarvik-2000
alone appears to maintain, at least temporarily, sufficient
cardiac output, as our patient with sustained ventricular
tachycardia remained fully awake.
Hemolysis. Hemolysis is one of the main concerns of axial
flow pumps, given the devices’ tremendous rotational speeds
(8,000 to 12,000 rpm). As illustrated in Figure 3, we found
evidence of mild blood trauma, likely due to mechanical
forces affecting the cellular blood components. Hemolysis
does not appear to pose a clinical problem thus far, as no
patient required a transfusion or had complications due to
increased red-cell turnover. We will perform ultrasonogra-
phy of the gallbladder every six months because of the
increased risk of pigment gallstone formation and related
complications.
Psychology. Many patients require psychological therapy
after LVAD implantation (23). Denial is a common coping
mechanism, but patients with an LVAD cannot ignore or
deny their condition. The patient has to change the batteries
several times a day and is constantly reminded of the device.
Professional psychological help, focusing on coping strate-
gies and treating depression, was perceived as beneficial by
two of our patients. All patients had an improved quality-
of-life score (Table 3).
Prognosis. We can only speculate on the long-term prog-
noses of these patients. It will depend on the device’s
durability, the incidence of late complications and the
course of the underlying myocardial disease. The wear and
tear of the device is very low according to the manufacturer
(Jarvik Heart, Inc., New York, New York). We are attempt-
ing to keep late complications at a minimum, with close
outpatient multidisciplinary follow-up. Long-term unload-
ing could potentially allow partial myocardial recovery or
stabilize the disease. Changes in myocardial gene expression
have been described with long-term unloading (24). Only a
few patients with a conventional LVAD implanted because
of chronic HF had sufficient myocardial recovery to allow
device explantation. Many of them later developed recurrent
HF (25). Native myocardial function is crucial, as the
Jarvik-2000 only assists the LV and depends on the heart’s
contractility. Therefore, continuous HF treatment with
administration of angiotensin-converting enzyme inhibitors
and beta-blockers appears to be essential in the long-term
management of these patients.
Conclusions. Our early experience with the permanent
Jarvik-2000 LVAD has been encouraging. It can be used in
patients with dilative or restrictive disease. There were no
device failures. All patients were discharged home. We
noted a low incidence of complications. The Jarvik-2000
might prove to be a valid tool in the physician’s armamen-
tarium for the long-term treatment of severe HF.
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